EXPLORING MARINE SEAWEED-DERIVED PHYTOCONSTITUENTS AS POTENTIAL THERAPEUTIC AGENTS AGAINST MYCOBACTERIUM TUBERCULOSIS: A REVIEW

Rashith A.*, Dr. Sathiya Balan G., Keerthana T., Dr. Venkata Rathina Kumar T.

ABSTRACT

Globally, 7.5 million individuals were diagnosed with tuberculosis (TB). TB is an infectious pulmonary ailment instigated by Mycobacterium tuberculosis. This surge exceeded pre-COVID levels (7.1 million in 2019) by 16%, and surpassed 2023 figures by 28%. Although drugs like Rifampicin, pyrazinamide, Isoniazid, Ethambutal and streptomycin are used as first line drugs were used in the treatment and control of tuberculosis progression, cause hepatic disorder and drug resistance may occurs. Natural source such and plants and marine organisms possess various secondary metabolites acts against mycobacterium in vitro. The secondary metabolites act by various mechanisms to supress the growth of mycobacterium and also enhance the immunity. But yet to evaluated in humans and have to be standardised properly to ensure the safety and efficacy of the natural sources. This review will focus on the various marine seaweed derived phytoconstituents in recent year shown a promising activity against Mycobacterium tuberculosis. More research is required to get new moiety in the treatment of tuberculosis.

Keywords: Mycobacterium tuberculosis, Seaweed, GC-MS, Anti-tubucular and Marine natural products.